Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Elevai Labs Inc (ELAB)

Elevai Labs Inc (ELAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 460
  • Shares Outstanding, K 20,805
  • Annual Sales, $ 1,710 K
  • Annual Income, $ -4,300 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta N/A
  • Price/Sales 0.17
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.32
  • Most Recent Earnings $-0.08 on 08/14/24
  • Next Earnings Date 12/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0161 +37.27%
on 11/06/24
0.1840 -87.99%
on 10/25/24
-0.0670 (-75.20%)
since 10/15/24
3-Month
0.0161 +37.27%
on 11/06/24
0.3900 -94.33%
on 08/26/24
-0.2780 (-92.64%)
since 08/15/24

Most Recent Stories

More News
10 Most Active Stocks On Stockwits In The Past Week With Message Volume Spurt

Cryptocurrencies, stocks that pulled back from their post-election highs, and some obscure securities were among those that saw huge message volumes in the past week.

QQQ : 496.57 (-2.38%)
AZI : 1.7200 (-7.53%)
TSLA : 320.72 (+3.07%)
SMCI : 18.58 (+3.16%)
ELAB : 0.0221 (-15.65%)
SPY : 585.75 (-1.28%)
GME : 26.59 (-2.85%)
DJT : 28.10 (+4.11%)
Elevai Labs Inc. Reports Strong Financial Results and Advances in Aesthetic Innovation, Including Successful $8 Million Public Offering

Elevai Labs announces strong financial results, innovative clinical advancements, and expansion of its patent portfolio in aesthetic treatments.Quiver AI SummaryElevai Labs Inc. reported strong financial...

ELAB : 0.0221 (-15.65%)
CORRECTION - Elevai Labs Inc.

ELAB : 0.0221 (-15.65%)
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

ELAB : 0.0221 (-15.65%)
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

ELAB : 0.0221 (-15.65%)
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

ELAB : 0.0221 (-15.65%)
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

ELAB : 0.0221 (-15.65%)
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

ELAB : 0.0221 (-15.65%)
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

ELAB : 0.0221 (-15.65%)
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

ELAB : 0.0221 (-15.65%)

Business Summary

ELEVAI Labs Inc. is a medical aesthetic company developing cutting-edge physician-dispensed skin care applications. The company solves unmet needs in the medical aesthetics space through a combination of cutting-edge science-driven and next-generation consumer applications. ELEVAI Labs Inc. is based...

See More

Key Turning Points

3rd Resistance Point 0.0326
2nd Resistance Point 0.0293
1st Resistance Point 0.0257
Last Price 0.0221
1st Support Level 0.0188
2nd Support Level 0.0155
3rd Support Level 0.0119

See More

52-Week High 4.2442
Fibonacci 61.8% 2.6291
Fibonacci 50% 2.1302
Fibonacci 38.2% 1.6312
Last Price 0.0221
52-Week Low 0.0161

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar